FDA clears icometrix’ image quantification software to monitor neurological disorders such as Multiple Sclerosis

Leuven - Antwerp, Belgium: 7 September 2016 - The health tech company icometrix obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their image quantification software. Outside the US, the software is already extensively used and offered via MSmetrix. The software quantifies key features of clinical MRI brain scans, which enable clinicians to monitor how their patient's brain changes over time, which is especially useful for Multiple Sclerosis. icometrix' software is the only solution currently available that has been scientifically validated and clinically approved for longitudinal measurements. This way, icometrix offers clinicians unrivalled access to unique information about disease progression and the effect of treatment upon brain structure.

More information on icometrix' website.

Next > Green Biologics and Acme Hardesty launch bio-based esters for personal care markets

Previous > Confo Therapeutics appoints Dr Cedric Ververken as Chief Executive Officer